GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InDex Pharmaceuticals Holding AB (OSTO:INDEX) » Definitions » Quick Ratio

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Quick Ratio : 6.39 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is InDex Pharmaceuticals Holding AB Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. InDex Pharmaceuticals Holding AB's quick ratio for the quarter that ended in Mar. 2024 was 6.39.

InDex Pharmaceuticals Holding AB has a quick ratio of 6.39. It generally indicates good short-term financial strength.

The historical rank and industry rank for InDex Pharmaceuticals Holding AB's Quick Ratio or its related term are showing as below:

OSTO:INDEX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43   Med: 7.71   Max: 54.9
Current: 6.39

During the past 10 years, InDex Pharmaceuticals Holding AB's highest Quick Ratio was 54.90. The lowest was 0.43. And the median was 7.71.

OSTO:INDEX's Quick Ratio is ranked better than
68.62% of 1539 companies
in the Biotechnology industry
Industry Median: 3.58 vs OSTO:INDEX: 6.39

InDex Pharmaceuticals Holding AB Quick Ratio Historical Data

The historical data trend for InDex Pharmaceuticals Holding AB's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InDex Pharmaceuticals Holding AB Quick Ratio Chart

InDex Pharmaceuticals Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.69 5.62 41.93 23.57 5.04

InDex Pharmaceuticals Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.70 9.87 9.01 5.04 6.39

Competitive Comparison of InDex Pharmaceuticals Holding AB's Quick Ratio

For the Biotechnology subindustry, InDex Pharmaceuticals Holding AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InDex Pharmaceuticals Holding AB's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InDex Pharmaceuticals Holding AB's Quick Ratio distribution charts can be found below:

* The bar in red indicates where InDex Pharmaceuticals Holding AB's Quick Ratio falls into.



InDex Pharmaceuticals Holding AB Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

InDex Pharmaceuticals Holding AB's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(296.615-0)/58.906
=5.04

InDex Pharmaceuticals Holding AB's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(278.431-0)/43.591
=6.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InDex Pharmaceuticals Holding AB  (OSTO:INDEX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


InDex Pharmaceuticals Holding AB Quick Ratio Related Terms

Thank you for viewing the detailed overview of InDex Pharmaceuticals Holding AB's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InDex Pharmaceuticals Holding AB (OSTO:INDEX) Business Description

Traded in Other Exchanges
N/A
Address
Berzelius vag 13, Solna, SWE, 171 65
InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Headlines

No Headlines